Загрузка...
Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen
OBJECTIVE: Tamoxifen is used as a complementary treatment for estrogen receptor (ER)-positive breast cancer (BCa), but many patients developed resistance. The aim of this study was to examine the role of syndecan-binding protein (SDCBP) silencing in ER-positive BCa cells. METHODS: In MCF-7/T47D cell...
Сохранить в:
| Опубликовано в: : | Cancer Biol Med |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Chinese Anti-Cancer Association
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5842332/ https://ncbi.nlm.nih.gov/pubmed/29545966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20892/j.issn.2095-3941.2017.0122 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|